Grunenthal GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH132572D
- Pages: 70
- November 2018
- Total Views:1157
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. It researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. The company provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal also focuses on discovering new methods to treat pain, developing new medical devices, and new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Germany.
Grunenthal GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 15
Grunenthal Acquires Rights to Zomic from AstraZeneca 16
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 17
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 18
Venture Financing 19
Thar Pharma Raises USD0.12 Million in Venture Financing 19
Thar Pharma Raises Additional USD2 Million in Venture Financing 20
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 21
Thar Pharma Raises Additional USD 0.08 Million In Venture Financing 22
Partnerships 23
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 23
Grunenthal and KU Leuven Enter into Research Agreement 25
Grunenthal Enters into Distribution Agreement with Merck 26
Helsinn and Grunenthal Enter into Agreement for Akynzeo 27
Grunenthal Enters into Agreement with Axxam 28
Patheon Enters into Co-Development Agreement with Grunenthal 29
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 30
Thar Pharma Enters into Co-Development Agreement 31
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 32
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 33
Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 34
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 35
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 36
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 38
Licensing Agreements 39
Grunenthal to Receive Rights for Nexium from AstraZeneca 39
Grunenthal to Receive Rights for Vimovo from AstraZeneca 40
Mundipharma Enters into Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with AstraZeneca 42
Mundipharma Enters Into Licensing Agreement With Grunenthal 43
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 45
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 46
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 47
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 48
Equity Offering 49
Thar Pharma Postpones IPO for USD50 Million 49
Asset Transactions 50
Depomed Acquires Rights of Cebranopadol from Grunenthal 50
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 52
Acquisition 54
Grunenthal Acquires Thar Pharma 54
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 55
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 56
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 57
Grunenthal GmbH-Key Competitors 58
Grunenthal GmbH-Key Employees 59
Grunenthal GmbH-Locations And Subsidiaries 60
Head Office 60
Other Locations & Subsidiaries 60
Recent Developments 63
Strategy And Business Planning 63
Oct 31, 2018: AstraZeneca signs USD 922m licensing deal with Grunenthal 63
May 10, 2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 64
Corporate Communications 65
Sep 01, 2017: Mark Fladrich Takes office as the New CCO of the Grunenthal Group 65
May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 66
Government and Public Interest 67
Nov 16, 2017: Research Consortium led by Grunenthal receives EUR 2 million grant from the European Fund for Regional Development and the State of North Rhine-Westphalia 67
May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 68
Product News 69
Jul 07, 2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
List Of Figure
List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
Grunenthal GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 15
Grunenthal Acquires Rights to Zomic from AstraZeneca 16
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 17
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 18
Thar Pharma Raises USD0.12 Million in Venture Financing 19
Thar Pharma Raises Additional USD2 Million in Venture Financing 20
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 21
Thar Pharma Raises Additional USD 0.08 Million In Venture Financing 22
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 23
Grunenthal and KU Leuven Enter into Research Agreement 25
Grunenthal Enters into Distribution Agreement with Merck 26
Helsinn and Grunenthal Enter into Agreement for Akynzeo 27
Grunenthal Enters into Agreement with Axxam 28
Patheon Enters into Co-Development Agreement with Grunenthal 29
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 30
Thar Pharma Enters into Co-Development Agreement 31
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 32
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 33
Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 34
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 35
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 36
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 38
Grunenthal to Receive Rights for Nexium from AstraZeneca 39
Grunenthal to Receive Rights for Vimovo from AstraZeneca 40
Mundipharma Enters into Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with AstraZeneca 42
Mundipharma Enters Into Licensing Agreement With Grunenthal 43
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 45
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 46
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 47
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 48
Thar Pharma Postpones IPO for USD50 Million 49
Depomed Acquires Rights of Cebranopadol from Grunenthal 50
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 52
Grunenthal Acquires Thar Pharma 54
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 55
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 56
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 57
Grunenthal GmbH, Key Competitors 58
Grunenthal GmbH, Key Employees 59
Grunenthal GmbH, Other Locations 60
Grunenthal GmbH, Subsidiaries 60
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Company Profile
Company Profile Title
Summary
Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. It researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. The company provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal also focuses on discovering new methods to treat pain, developing new medical devices, and new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Germany.
Grunenthal GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 15
Grunenthal Acquires Rights to Zomic from AstraZeneca 16
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 17
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 18
Venture Financing 19
Thar Pharma Raises USD0.12 Million in Venture Financing 19
Thar Pharma Raises Additional USD2 Million in Venture Financing 20
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 21
Thar Pharma Raises Additional USD 0.08 Million In Venture Financing 22
Partnerships 23
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 23
Grunenthal and KU Leuven Enter into Research Agreement 25
Grunenthal Enters into Distribution Agreement with Merck 26
Helsinn and Grunenthal Enter into Agreement for Akynzeo 27
Grunenthal Enters into Agreement with Axxam 28
Patheon Enters into Co-Development Agreement with Grunenthal 29
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 30
Thar Pharma Enters into Co-Development Agreement 31
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 32
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 33
Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 34
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 35
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 36
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 38
Licensing Agreements 39
Grunenthal to Receive Rights for Nexium from AstraZeneca 39
Grunenthal to Receive Rights for Vimovo from AstraZeneca 40
Mundipharma Enters into Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with AstraZeneca 42
Mundipharma Enters Into Licensing Agreement With Grunenthal 43
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 45
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 46
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 47
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 48
Equity Offering 49
Thar Pharma Postpones IPO for USD50 Million 49
Asset Transactions 50
Depomed Acquires Rights of Cebranopadol from Grunenthal 50
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 52
Acquisition 54
Grunenthal Acquires Thar Pharma 54
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 55
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 56
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 57
Grunenthal GmbH-Key Competitors 58
Grunenthal GmbH-Key Employees 59
Grunenthal GmbH-Locations And Subsidiaries 60
Head Office 60
Other Locations & Subsidiaries 60
Recent Developments 63
Strategy And Business Planning 63
Oct 31, 2018: AstraZeneca signs USD 922m licensing deal with Grunenthal 63
May 10, 2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 64
Corporate Communications 65
Sep 01, 2017: Mark Fladrich Takes office as the New CCO of the Grunenthal Group 65
May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 66
Government and Public Interest 67
Nov 16, 2017: Research Consortium led by Grunenthal receives EUR 2 million grant from the European Fund for Regional Development and the State of North Rhine-Westphalia 67
May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 68
Product News 69
Jul 07, 2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
List Of Figure
List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
Grunenthal GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 15
Grunenthal Acquires Rights to Zomic from AstraZeneca 16
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 17
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 18
Thar Pharma Raises USD0.12 Million in Venture Financing 19
Thar Pharma Raises Additional USD2 Million in Venture Financing 20
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 21
Thar Pharma Raises Additional USD 0.08 Million In Venture Financing 22
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 23
Grunenthal and KU Leuven Enter into Research Agreement 25
Grunenthal Enters into Distribution Agreement with Merck 26
Helsinn and Grunenthal Enter into Agreement for Akynzeo 27
Grunenthal Enters into Agreement with Axxam 28
Patheon Enters into Co-Development Agreement with Grunenthal 29
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 30
Thar Pharma Enters into Co-Development Agreement 31
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 32
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 33
Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 34
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 35
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 36
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 38
Grunenthal to Receive Rights for Nexium from AstraZeneca 39
Grunenthal to Receive Rights for Vimovo from AstraZeneca 40
Mundipharma Enters into Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with AstraZeneca 42
Mundipharma Enters Into Licensing Agreement With Grunenthal 43
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 45
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 46
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 47
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 48
Thar Pharma Postpones IPO for USD50 Million 49
Depomed Acquires Rights of Cebranopadol from Grunenthal 50
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For USD 230 Million 52
Grunenthal Acquires Thar Pharma 54
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 55
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 56
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 57
Grunenthal GmbH, Key Competitors 58
Grunenthal GmbH, Key Employees 59
Grunenthal GmbH, Other Locations 60
Grunenthal GmbH, Subsidiaries 60
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020